GB202107713D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB202107713D0
GB202107713D0 GBGB2107713.6A GB202107713A GB202107713D0 GB 202107713 D0 GB202107713 D0 GB 202107713D0 GB 202107713 A GB202107713 A GB 202107713A GB 202107713 D0 GB202107713 D0 GB 202107713D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2107713.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADC Therapeutics SA
MedImmune Ltd
Original Assignee
ADC Therapeutics SA
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADC Therapeutics SA, MedImmune Ltd filed Critical ADC Therapeutics SA
Priority to GBGB2107713.6A priority Critical patent/GB202107713D0/en
Publication of GB202107713D0 publication Critical patent/GB202107713D0/en
Priority to PCT/EP2022/063158 priority patent/WO2022248268A1/en
Ceased legal-status Critical Current

Links

GBGB2107713.6A 2021-05-28 2021-05-28 Combination therapy Ceased GB202107713D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2107713.6A GB202107713D0 (en) 2021-05-28 2021-05-28 Combination therapy
PCT/EP2022/063158 WO2022248268A1 (en) 2021-05-28 2022-05-16 Combination therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2107713.6A GB202107713D0 (en) 2021-05-28 2021-05-28 Combination therapy

Publications (1)

Publication Number Publication Date
GB202107713D0 true GB202107713D0 (en) 2021-07-14

Family

ID=76741420

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2107713.6A Ceased GB202107713D0 (en) 2021-05-28 2021-05-28 Combination therapy

Country Status (1)

Country Link
GB (1) GB202107713D0 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Genbank", Database accession no. CAA78163
"Guideline on clinical trials in small populations", 1 February 2007
ANGEW CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
CARTER, P., NATURE REVIEWS IMMUNOLOGY, vol. 6, 2006, pages 343 - 357
CAS , no. 7 95058-81-4
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
FLYNN ET AL., MOL CANCER THER, 2016
HAMANN P., EXPERT OPIN. THER. PATENTS, vol. 15, no. 9, 2005, pages 1087 - 1103
JANEWAY, C.TRAVERS, P.WALPORT, M.SHLOMCHIK: "Immuno Biology", 2001, GARLAND PUBLISHING
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOVTUN ET AL., CANCER RES., vol. 66, no. 4, 2006, pages 2328 - 2337
LAMBERT J., CURRENT OPIN. IN PHARMACOL., vol. 5, 2005, pages 543 - 549
LONBERG, CURR. OPINION, vol. 20, no. 4, 2008, pages 450 - 459
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212
SYRIGOSEPENETOS, ANTICANCER RESEARCH, vol. 19, 1999, pages 605 - 614
TOSCHI ET AL., FUTURE ONCOLOGY, vol. 1, no. 1, 2005, pages 7 - 17
TRAIL ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337
WU ET AL., NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1137 - 1145
XIE ET AL., EXPERT. OPIN. BIOL. THER., vol. 6, no. 3, 2006, pages 281 - 291
ZAMMARCHI ET AL., AACR ANNUAL MEETING, 14 April 2018 (2018-04-14)

Similar Documents

Publication Publication Date Title
GB202111288D0 (en) Combination therapy
GB202108303D0 (en) Therapy
GB202004189D0 (en) Combination therapy
IL304223A (en) Combination therapy
GB202109377D0 (en) Combination therapy
GB202109375D0 (en) Combination therapy
GB202109373D0 (en) Combination therapy
GB202107824D0 (en) Combination therapy
GB202107706D0 (en) Combination therapy
GB202107709D0 (en) Combination therapy
GB202107713D0 (en) Combination therapy
GB202104037D0 (en) Combination therapy
GB202015916D0 (en) Combination therapy
GB202012161D0 (en) Combination therapy
GB202009178D0 (en) Combination therapy
GB202117706D0 (en) Therapy
GB202111035D0 (en) Therapy
GB202109893D0 (en) PeptiBAC therapy
GB202104427D0 (en) Therapy
GB202103164D0 (en) Therapy
GB202102211D0 (en) PeptiBAC therapy
GB202019218D0 (en) Therapy
GB202017598D0 (en) Therapy
GB202017554D0 (en) Therapy
GB202015780D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)